Therefore, a better understanding of the mechanisms of action of anti-PD-L1 (or anti-PD-1) mAb therapy and the impact of this therapy on each component of the tumor immune microenvironment will help improve the precision of cancer immunotherapeutics in the future. The gene discussed is CD274; the disease is neoplasm.